Several single-arm Phase II trials have evaluated VEGFR TKIs [6–10, 12–14, 19–21, 25] for the treatment of advanced thyroid cancer (summarized in Online Resource 1). This evidence concerns the gene KDR and thyroid gland carcinoma.